Thermo Fisher Scientific Inc.

Money Moves

Raised 2026 guidance after 5% organic Q2 growth

Thermo Fisher Scientific grew 5% organically in the second quarter, its fastest pace since 2021. The company raised its full-year guidance and its chief executive says orders are running ahead of revenue.

Updated Sep 17

New Capabilities

Major competitor after acquiring Olink

Alamar Biosciences raised $191 million in its initial public offering on April 17, 2026 (nearly double the $100 million it originally planned) after investor demand exceeded available shares by more than tenfold. Shares priced at $17, opened at $22.60, and closed at $22.00, a 29% first-day gain that gave the company a market capitalization of roughly $1.53 billion. The Fremont, California company develops technology that detects proteins in blood at concentrations so low that conventional tests miss them entirely, potentially catching diseases years earlier than current methods allow. CEO and founder Yuling Luo told Reuters the company plans to use the proceeds to expand into cancer, cardiology, and other major disease areas. The company reported $74.2 million in revenue for fiscal year 2025 (nearly triple the year prior), creating a baseline for investors to measure future commercial growth.

Updated May 31

Money Moves

Acquirer; integrating Clario into its Laboratory Products and Biopharma Services segment

Thermo Fisher Scientific, one of the world's largest scientific instrumentation companies, closed its $8.875 billion cash purchase of Clario Holdings on March 24, 2026. The deal, first announced in October 2025, includes up to $525 million in additional payments tied to Clario's near-term performance, bringing the potential total to $9.4 billion.

Updated May 30

Money Moves

Acquired Solventum's Purification & Filtration business for $4.1 billion

Over the past 12 months, four major deals totaling over $15 billion have transformed the industrial filtration industry. Parker Hannifin agreed to pay $9.25 billion for Filtration Group in November 2025 (pending regulatory approval).

Updated May 19